Clin2
NCT07327489Worth exploringRecruiting

Live tumor biopsy study to predict immunotherapy response

CancerImmunotherapyAdvanced Solid Tumors CancerBladder CancerTNBC, Triple Negative Breast CancerColorectal CancerDMMR Colorectal CancerMSI-H Colorectal Cancer

Part of Cancer, Digestive system, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.

This trial studies how well immunotherapy might work by analyzing fresh tumor biopsies. It may help predict which treatments are best for your cancer.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
2,000 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You are 18 years or older and willing to take part.
  • You have a suspected or confirmed cancer that will be checked with a biopsy (a small tissue sample).
  • If you are newly diagnosed, you have not had any cancer treatment yet. If you have been treated before, the biopsy must be done before your next treatment starts.
  • You do not have an autoimmune disease, organ transplant, chronic kidney or liver disease that would prevent immunotherapy.
  • You are not severely immunocompromised (e.g., on immunosuppressants, HIV on antiretrovirals, or a transplant recipient).
  • You are not pregnant.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07376512Not yet recruiting
Blood test to predict immunotherapy response in lung cancer and melanoma

This trial studies whether a simple blood test can predict how well your immune system will respond to immunotherapy (such as Keytruda or Opdivo). You may qualify if you have lung cancer (NSCLC) or advanced melanoma and are about to start this type of treatment for the first time.

Besançon
NCT07246759Not yet recruiting
Blood test to predict immunotherapy benefit in advanced cancer

This trial is testing a simple blood test to see if it can predict how well immunotherapy will work for people with advanced cancer. It's for those newly diagnosed with certain cancers and about to start immunotherapy as their first treatment.

Heidelberg
NCT06227728Recruiting
Predicting immunotherapy response in advanced cancer

This study uses blood and tumor samples to find markers that predict whether immunotherapy will work for people with stage IV cancer. The goal is to better match treatments to patients.

Ho Chi Minh City, Hồ Chí Minh
NCT04243720Recruiting
Study of immune resistance after immunotherapy

This trial studies why some solid cancers stop responding to immune-based drugs (like anti–PD-1/PD-L1) and what can be done next. You may be eligible if your cancer has progressed after immunotherapy and you can safely undergo a tumor needle biopsy.

Toronto, Ontario
NCT05231655Recruiting
Study testing fresh tumor tissue from cancer surgery or biopsy

This study collects fresh samples of tumor tissue during procedures like surgery, biopsy, or TURBT to test a cancer therapy outside the body. It may help researchers learn which treatments work better for different solid cancers.

Sheffield, South Yorkshire
NCT05600933Enrolling by invitation
Providing tumor samples to find new treatment targets

This study collects tumor tissue and related blood tests from people who already need a biopsy or surgery as part of their usual care. Researchers use the samples to learn what drives the tumor and how the tumor environment may affect treatment, which could help develop future therapies.

Bethesda, Maryland

Hear when a new Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.